Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 09 2020
03 09 2020
Historique:
received:
27
12
2019
accepted:
18
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
16
3
2021
Statut:
epublish
Résumé
Available epidemiological reports on follicular lymphoma (FL) often highlight a significant discrepancy between its high and low incidence rates in Western and Eastern Europe, respectively. The reasons behind that difference are not fully understood, but underreporting is typically presumed as one of the main factors. This study aimed to assess FL epidemiology in Poland based on 2000-2014 data from the Polish National Cancer Registry, which has 100% population coverage and over 90% completeness of the registration. All cases were coded according to ICD-10 and ICD-O-3 recommendations. The total number of registered FL cases was 3,928 with crude (CR) and standardized (SR) incidence rates of 0.72/10
Identifiants
pubmed: 32884080
doi: 10.1038/s41598-020-71579-6
pii: 10.1038/s41598-020-71579-6
pmc: PMC7471935
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14610Références
Sant, M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116, 3724–3734 (2010).
doi: 10.1182/blood-2010-05-282632
Miranda-Filho, A. et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control CCC 30, 489–499 (2019).
doi: 10.1007/s10552-019-01155-5
Szumera-Ciećkiewicz, A. et al. Distribution of lymphomas in Poland according to World Health Organization classification: analysis of 11718 cases from National Histopathological Lymphoma Register project: the Polish Lymphoma Research Group study. Int. J. Clin. Exp. Pathol 7, 3280–3286 (2014).
pubmed: 25031749
pmcid: 4097276
Swerdlow, S. H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edn. (IARC, Lyon, 2017).
Xerri, L. et al. The heterogeneity of follicular lymphomas: from early development to transformation. Virchows Archiv. Int. J. Pathol. 468, 127–139 (2016).
doi: 10.1007/s00428-015-1864-y
Carbone, A. et al. Follicular lymphoma. Nat. Rev. Dis. Primers 5, 83 (2019).
doi: 10.1038/s41572-019-0132-x
de Jong, D. & de Boer, J. P. Predicting transformation in follicular lymphoma. Leuk. Lymph. 50, 1406–1411 (2009).
doi: 10.1080/10428190903093815
Fischer, T., Zing, N. P. C., Chiattone, C. S., Federico, M. & Luminari, S. Transformed follicular lymphoma. Ann. Hematol. 97, 17–29 (2018).
doi: 10.1007/s00277-017-3151-2
Oishi, N., Montes-Moreno, S. & Feldman, A. L. In situ neoplasia in lymph node pathology. Semin. Diagn. Pathol. 35, 76–83 (2018).
doi: 10.1053/j.semdp.2017.11.001
Bray, F., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
Yuda, S. et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann. Hematol. 95, 2017–2022 (2016).
doi: 10.1007/s00277-016-2800-1
Armitage, J. O. & Longo, D. L. Is watch and wait still acceptable for patients with low-grade follicular lymphoma?. Blood 127, 2804–2808 (2016).
doi: 10.1182/blood-2015-11-632745
Smedby, K. E. & Ponzoni, M. The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections. J. Intern. Med. 282, 360–370 (2017).
doi: 10.1111/joim.12684
Alavanja, M. C. R. et al. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the agricultural health study. PLoS ONE 9, e109332–e109332 (2014).
doi: 10.1371/journal.pone.0109332
Vijgen, J. et al. Hexachlorocyclohexane (HCH) as new Stockholm Convention POPs: a global perspective on the management of Lindane and its waste isomers. Environ. Sci. Pollut. Res. Int. 18, 152–162 (2011).
doi: 10.1007/s11356-010-0417-9
Vijgen, J., de Borst, B., Weber, R., Stobiecki, T. & Forter, M. HCH and lindane contaminated sites: European and global need for a permanent solution for a long-time neglected issue. Environ. Pollut. (Barking, Essex : 1987) 248, 696–705 (2019).
Chihara, D. et al. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev. Anticancer Ther 15, 531–544 (2015).
doi: 10.1586/14737140.2015.1023712
Kroll, M. E. et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br. J. Cancer 107, 879–887 (2012).
doi: 10.1038/bjc.2012.333
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet (London, England) 389, 1885–1906 (2017).
Ng, M. et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA 311, 183–192 (2014).
doi: 10.1001/jama.2013.284692
Linet, M. S. et al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl. Cancer Inst. Monogr. 2014, 26–40 (2014).
doi: 10.1093/jncimonographs/lgu006
Psaltopoulou, T. et al. Alcohol consumption and risk of hematological malignancies: a meta-analysis of prospective studies. Int. J. Cancer 143, 486–495 (2018).
doi: 10.1002/ijc.31330
World Health Organization. www.who.int/substance_abuse/publications/global_alcohol_report/profiles/pol.pdf?ua=1 .
Wojtyniak, B., Moskalewicz, J., Stokwiszewski, J. & Rabczenko, D. Gender-specific mortality associated with alcohol consumption in Poland in transition. Addiction (Abingdon, England) 100, 1779–1789 (2005).
doi: 10.1111/j.1360-0443.2005.01247.x
Yakovlev, E. Alcoholism and mortality in Eastern Europe: https://wol.iza.org/articles/alcoholism-and-mortality-in-eastern-europe/long . in IZA World of Labor (2015).
WHO Global Status Report On Alcohol and Health. Geneva: WHO, 2011.
Baecklund, F. et al. Possible interaction between cigarette smoking and HLA-DRB1 variation in the risk of follicular lymphoma. Am. J. Epidemiol. 185, 681–687 (2017).
doi: 10.1093/aje/kww118
Conde, L. et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat. Genet. 42, 661–664 (2010).
doi: 10.1038/ng.626
Skibola, C. F. et al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am. J. Hum. Genet. 95, 462–471 (2014).
doi: 10.1016/j.ajhg.2014.09.004
Baecklund, F. et al. A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. BMC Med Genet 15, 113–113 (2014).
doi: 10.1186/s12881-014-0113-6
Paszkiewicz-Kozik, E. et al. Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma. Med. Oncol. (Northwood, London, England) 26, 16–21 (2009).
doi: 10.1007/s12032-008-9071-1
Walewski, J. et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance: a multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br. J. Haematol. 188, 898–906 (2020).
doi: 10.1111/bjh.16264
Walewski, J. et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med. Oncol. (Northwood, London, England) 18, 141–148 (2001).
doi: 10.1385/MO:18:2:141
National Cancer Intitute. https://seer.cancer.gov/statfacts/html/follicular.html . in The Surveillance, Epidemiology, and End Results
Sarkozy, C. et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J. Clin. Oncol. 37, 144–152 (2019).
doi: 10.1200/JCO.18.00400
Fritz, A. ICD-O-3 terminology approved for use with cases diagnosed January 1, 2014 and after. J. Regis. Manag. 40, 140–143 (2013).
https://icd.who.int/browse10/2016/en#/C81-C96 .
Wojciechowska, U., Olasek, P., Czauderna, K. & Didkowska, J. Nowotwory złośliwe w Polsce w 2014 roku. Cancer in Poland in 2014., (Centrum Onkologii Instytut im. Marii Skłodowskiej-Curie, Warszawa 2016).